First AD

Second AD

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Updates in HER2+ Early and Metastatic Breast Cancer

Peer Exchange

The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.

Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

Incidence and Typical Prognosis of HER2+ Early Breast Cancer

Neoadjuvant Treatment of HER2+ Early Breast Cancer

De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)

Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022

HER2+ mBC: First-Line Treatment Regimens

Second-Line Treatment of HER2+ mBC and Recent Data Updates

Options for Third- and Further-Line Treatment of HER2+ mBC

Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC

Emerging Data and Investigational Agents in HER2+ mBC

Unmet Needs and the Future of HER2+ Breast Cancer Treatment